A Randomized, Double-Blind, Parallel Group Clinical Study To Evaluate Efficacy And Safety Of UO ABG 01 In The Management Of Borderline Cardio Vascular Risk Factors
Not Applicable
- Conditions
- Health Condition 1: I52- Other heart disorders in diseasesclassified elsewhere
- Registration Number
- CTRI/2023/10/058501
- Lead Sponsor
- Xtractiva Life Science Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male or female subjects between 25 to 65 years of age
Ability to understand the risks/benefits of the protocol
Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential must be amenorrheic for at least 1 years or had a hysterectomy and/or bilateral oophorectomy
Serum triglycerides > 115mg/dL and less than < 199 mg/dL
If former smoker (previously smoked =10 cigarettes/day for at least 1 year, cessation for at least 6 months
Willing to give written informed consent and willing to comply with trial protocol
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method